Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
RA Larson, M Boogaerts, E Estey, C Karanes… - Leukemia, 2002 - nature.com
We analyzed the safety and efficacy of Mylotarg (gemtuzumab ozogamicin, an antibody-
targeted chemotherapy consisting of a humanized anti-CD33 antibody linked to …
targeted chemotherapy consisting of a humanized anti-CD33 antibody linked to …
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancer
F Fang, C Balch, J Schilder, T Breen, S Zhang… - Cancer, 2010 - Wiley Online Library
BACKGROUND: Aberrant DNA methylation is a hallmark of cancer, and DNA
methyltransferase inhibitors have demonstrated clinical efficacy in hematologic …
methyltransferase inhibitors have demonstrated clinical efficacy in hematologic …
Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidine
M LuÈbbert, P Wijermans, R Kunzmann… - British journal of …, 2001 - Wiley Online Library
Decitabine (5‐aza‐2′‐deoxycytidine) acts as a powerful demethylating agent in vitro.
Clinically, low‐dose decitabine ameliorates cytopenias including induction of trilineage …
Clinically, low‐dose decitabine ameliorates cytopenias including induction of trilineage …
Decitabine—bedside to bench
Y Oki, E Aoki, JPJ Issa - Critical reviews in oncology/hematology, 2007 - Elsevier
PURPOSE OF THE REVIEW: Epigenetic changes marked by DNA methylation are known to
contribute to the malignant transformation of cells by silencing critical genes. Decitabine …
contribute to the malignant transformation of cells by silencing critical genes. Decitabine …
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
S Sacchi, HM Kantarjian, S O'Brien… - … Journal of the …, 1999 - Wiley Online Library
BACKGROUND The prognoses of patients with chronic myelogenous leukemia in blastic
phase (CML‐BP) are extremely poor. Treatment of patients with nonlymphoid CML‐BP is …
phase (CML‐BP) are extremely poor. Treatment of patients with nonlymphoid CML‐BP is …
[HTML][HTML] Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter
Q Zhang, PN Raghunath, E Vonderheid… - The American journal of …, 2000 - Elsevier
SHP-1 is an important negative regulator of signaling by several receptors including
receptors for interleukin-2 (IL-2R) and other cytokines. SHP-1 acts by dephosphorylating the …
receptors for interleukin-2 (IL-2R) and other cytokines. SHP-1 acts by dephosphorylating the …
Decitabine in the treatment of acute myeloid leukemia in elderly patients
P Malik, AF Cashen - Cancer management and research, 2014 - Taylor & Francis
The majority of patients with acute myeloid leukemia (AML) are elderly and have a poor
prognosis despite induction therapy. Decitabine, a DNA-hypomethylating agent that induces …
prognosis despite induction therapy. Decitabine, a DNA-hypomethylating agent that induces …
DNA methylation changes in multiple myeloma
O Galm, S Wilop, J Reichelt, E Jost, G Gehbauer… - Leukemia, 2004 - nature.com
Using a candidate gene approach, we analyzed the methylation status of the promoter-
associated CpG islands of 11 well-characterized tumor suppressor genes by methylation …
associated CpG islands of 11 well-characterized tumor suppressor genes by methylation …
A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia
DNA hypermethylation and histone deacetylation are pathways of leukemia resistance. We
investigated the tolerability and efficacy of decitabine and vorinostat plus chemotherapy in …
investigated the tolerability and efficacy of decitabine and vorinostat plus chemotherapy in …
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS
DNA methylation abnormalities have recently emerged as one of the most frequent
molecular changes in hematopoietic neoplasms. Since methylation and transcriptional …
molecular changes in hematopoietic neoplasms. Since methylation and transcriptional …